

TWO NEW CERAMIDES FROM *Zephyranthes candida*Zhiping Wu,<sup>1,2</sup> Yu Chen,<sup>2</sup> Xu Feng,<sup>2\*</sup> Bing Xia,<sup>2</sup>  
Ming Wang,<sup>2</sup> and Yunfa Dong<sup>2</sup>

UDC 547.298

Two new ceramides were isolated from the bulbs of *Zephyranthes candida*. Their structures were established as (2S,3S,4R,13E)-1,3,4-trihydroxy-2-[(2'R)-2'-hydroxytetracosanoylamino]-13-octadecene, named zephyranamide A (**1**) and (2S,3S,4R)-1,3,4-trihydroxy-2-octacosanoylaminohexadecene, named zephyranamide B (**2**). The structures of the new compounds were elucidated by spectral techniques including <sup>1</sup>H NMR, <sup>13</sup>C NMR, as well as HSQC, HMBC, DEPT, and COSY.

**Key words:** Amaryllidaceae, *Zephyranthes candida*, ceramide, zephyranamide A, zephyranamide B.

*Zephyranthes candida* belongs to the Amaryllidaceae family. It is mainly distributed in the temperate zone of Western Hemisphere and is used as an ornamental and medicinal plant in China. The genus *Zephyranthes* is widely used as folk medicine in many countries. *Z. candida* has been employed in Africa as a treatment for diabetes mellitus, and *Z. parulla* appears in the history of Peru as a treatment for tumors [1]. *Z. rosea* and *Z. flava* are used for a variety of therapeutic purposes in India [2–4]. Herein we describe the isolation and structure elucidation of two new ceramides, named zephyranamide A (**1**) and zephyranamide B (**2**), from the bulbs of this plant. To the best of our knowledge, this is the first isolation of ceramides from a plant in the genus *Zephyranthes* and even the family Amaryllidaceae.

The molecular formula of zephyranamide A (**1**) was established to be C<sub>42</sub>H<sub>83</sub>NO<sub>5</sub> by its positive ESI-MS data for the [M+H]<sup>+</sup> at *m/z* 682. The IR spectrum showed absorption bands at 3334 and 3202, 2902 and 1623, 1527, and 1482, and 710 cm<sup>-1</sup> indicating the presence of hydroxyl, amide carbonyl functions, and olefinic carbons, respectively, and the <sup>1</sup>H and <sup>13</sup>C NMR spectrum suggested that **1** and **2** have the ceramide nature [5, 6]. The <sup>1</sup>H NMR spectrum of **1** (Table 1) displayed a downfield doublet at δ<sub>H</sub> 8.55 (1H, d, J = 8.9 Hz, NH), six olefinic, oxygenated, or other heteroatomized protons between δ<sub>H</sub> 4.25–5.52, as well as the signals of six methyl protons at δ<sub>H</sub> 0.87 (6H, br.t, J = 6.5 Hz, H-18 and H-24') and a very strong aliphatic methylene band at δ<sub>H</sub> 1.25–1.36. Signals of a *trans*-olefinic bond at δ<sub>H</sub> 5.52 (1H, dt, J = 14.6, 8.8 Hz, H-13) and δ<sub>H</sub> 5.49 (1H, dt, J = 14.6, 8.8 Hz, H-14) and five characteristic signals of geminal protons to hydroxyl groups were observed at δ<sub>H</sub> 4.61 (1H, m, H-2'), 4.41 (1H, dd, J = 10.5, 4.7 Hz, H-1a), 4.48 (1H, dd, J = 10.5, 4.6 Hz, H-1b), 4.34 (1H, dd, J = 5.2, 3.7 Hz, H-3), and 4.25 (1H, m, H-4). Another signal at low field was observed at δ<sub>H</sub> 5.08 (1H, m, H-2) for a methine proton vicinal to the nitrogen atom of an amide linkage. The <sup>13</sup>C NMR (Table 1) and DEPT spectral data of **1** showed one quaternary carbon at δ<sub>C</sub> 175.2 (C-1'), two olefinic methine carbons at δ<sub>C</sub> 130.2 (C-13 or C-14) and 130.8 (C-13 or C-14), as well as five oxygenated or other heteroatomized carbons at δ<sub>C</sub> 76.9 (C-3), 73.1 (C-4), 72.5 (C-2'), 62.1 (C-1), and 53.1 (C-2), aliphatic methylenes between δ<sub>C</sub> 29.6–30.4, and two terminal methyls at δ<sub>C</sub> 14.3 (C-18 and C-24'). The low-field doublet at δ<sub>H</sub> 8.55 (NH) was deuterium-exchangeable, and there was no correlation from this signal to any carbon in the HSQC spectrum of **1**. On the other hand, a correlation from δ<sub>H</sub> 8.55 (NH) to δ<sub>H</sub> 5.08 (1H, m, H-2), and correlations from δ<sub>H</sub> 8.55 (NH) to δ<sub>C</sub> 62.1 (C-1), 53.1 (C-2), 76.9 (C-3), 175.2 (C-1'), and 72.5 (C-2') were observed in the <sup>1</sup>H–<sup>1</sup>H COSY and HMBC spectra of **1**, respectively. The chemical shifts of the allylic methylene carbons in **1** were assigned at δ<sub>C</sub> 33.2 (C-12 or C-15) and 33.2 (C-12 or C-15) based on the clearly observed HMBC correlations from the olefinic signals at δ<sub>H</sub> 5.52 and 5.49 (2H, m, H-13 and H-14) to these two carbon signals (Fig. 1).

1) College of Life Science, Nanjing Agricultural University, Nanjing 210095, P. R. China; 2) Jiangsu Center for Research & Development of Medicinal Plants, Jiangsu Institute of Botany, Chinese Academy of Sciences/Nanjing Botanical Garden Mem. Sun Yat-Sen, Nanjing, 210014, P. R. China, fax: +86 25 84347084, e-mail: fengxu@mail.cnbg.net. Published in *Khimiya Prirodnykh Soedinenii*, No. 6, pp. 695–698, November–December, 2009. Original article submitted May 30, 2008.

TABLE 1.  $^1\text{H}$  NMR (500 MHz) and  $^{13}\text{C}$  NMR (125 MHz) as well as COSY Spectral Data of Compound **1** in  $\text{C}_5\text{D}_5\text{N}$  ( $\delta$ , ppm, J/Hz)

C atom	$\delta_{\text{H}}$ (HSQC)	$\delta_{\text{C}}$	$^1\text{H}$ - $^1\text{H}$ COSY
1a	4.41 (dd, J = 10.5, 4.7)	62.1	H-2
1b	4.48 (dd, J = 10.5, 4.6)	62.1	
2	5.08 (m)	53.1	H-1, H-3, NH
3	4.34 (dd, J = 5.2, 3.7)	76.9	H-2, H-4
4	4.25 (m)	73.1	H-3, H-5
5a, 5b	1.92, 2.25 (m)	34.2	H-4, H-6
6	1.92 (m)	26.7	H-5, H-7
7-11	1.25-1.36 (br.s)	29.6-30.4	
12	2.15 (m)	33.2	H-11, H-13
13	5.52 (dt, J = 14.6, 8.8)	130.2	H-12, H-14
14	5.49 (dt, J = 14.6, 8.8)	130.8	H-13, H-15
15	1.98 (m)	33.2	H-14, H-16
16	1.22 (m)	32.2	
17	1.22 (br.s)	23.0	
18	0.87 (t, J = 6.5)	14.3	
NH	8.55 (d, J = 8.9)	-	H-2
1'	-	175.2	H-3'
2'	4.61 (m)	72.5	H-2', H-4'
3'a, 3'b	2.21 (m), 2.02 (m)	35.8	H-3', H-5'
4'	1.92 (m)	26.7	H-4', H-(6'-22')
5'	1.75 (m)	25.9	
6'-22'	1.25-1.36 (br.s)	29.6-30.4	
23'	1.22 (br.s)	23.0	
24'	0.87 (t, J = 6.5)	14.3	H-(6'-22')

TABLE 2.  $^1\text{H}$  NMR (500 MHz) and  $^{13}\text{C}$  NMR (125 MHz) as well as COSY Spectral Data of Compound **2** in  $\text{C}_5\text{D}_5\text{N}$  ( $\delta$ , ppm, J/Hz)

C atom	$\delta_{\text{H}}$ (HSQC)	$\delta_{\text{C}}$	$^1\text{H}$ - $^1\text{H}$ COSY
1a	4.49 (dd, J = 10.9, 4.9)	62.3	H-2
1b	4.45 (dd, J = 11.7, 5.8)	62.3	
2	5.06 (m)	53.8	H-1, H-3, NH
3	4.37 (dd, J = 5.9, 5.2)	76.8	H-2, H-4
4	4.24 (m)	73.1	H-3, H-5
5	1.92 (m)	34.1	H-4
6	1.78 (m)	26.7	
7-13	1.23-1.44 (br.s)	29.7-30.4	
14	1.24 (m)	23.0	
15	1.22 (m)	32.2	
16	0.87 (t, J = 6.7)	14.3	
NH	8.39 (d, J = 8.5)	-	H-2
1'	-	173.3	
2'	2.45 (t, J = 7.5)	36.9	H-3'
3'	1.78 (m)	26.3	H-2'
4'-25'	1.23-1.44 (br.s)	29.7-30.4	
26'	1.24 (m)	23.0	
27'	1.22 (m)	32.2	
28'	0.87 (t, J = 6.7)	14.3	




Fig. 1. Structures and key HMBC correlations (H→C) of **1** and **2**.

Since the chemical shifts of allylic methylene carbons are different when alkene double bonds are *cis*-oriented ( $\delta_C \approx 27$  ppm) compared with when they are *trans*-oriented ( $\delta_C \approx 32$  ppm) [7, 8], the 13,14 alkenyl bond in compound **1** was assigned to the *E* configuration. The presence of 2-amino and 1,2',3,4 tetrahydroxyl groups as well as the 13,14 double bond in the main chain was established from the ESI-MS fragmentation pattern analysis [9–11]. The positive ESI-MS of **1** showed a quasimolecular ion at  $m/z$  682  $[M+H]^+$ , and the number of carbons in the long chain base (LCB) and the fatty acid (FA) were determined to be 18 and 24, respectively. Further investigation of the ESI-MS showed some important fragment ions at  $m/z$  664, 640, 625, 599, 382, 367, 309, 282, 268, and 255, suggesting the double bond to be located at C-13 and C-14. This was confirmed in the ESI-MS of **1**, which displayed the characteristic peaks at  $m/z$  625  $[M+H-C_4H_9]^+$  and 599  $[M+H-C_6H_{11}]^+$ . On the other hand, the ESI-MS spectrum of compound **1** additionally displayed a small but crucially important peak at  $m/z$  640  $[M+H-C_3H_6]^+$  formed by elimination of propylene through McLafferty rearrangement [12, 13], which further confirmed the position of the double bond (Fig. 2). Based on the  $^1H$  NMR chemical shifts of the chiral center and the data of optical rotation compared with those of the natural and synthetic sphingolipids [14, 16], compound **1** has a sphingosine moiety with (2*S*,3*S*,4*R*,13*E*) geometry. Based on this information, the structure of compound **1** was determined to be (2*S*,3*S*,4*R*,13*E*)-1,3,4-trihydroxy-2-[(2'*R*)-2'-hydroxytetracosanoylamino]-13-octadecene, named zephyranamide A.

Zephyranamide B (**2**) has the molecular formula  $C_{44}H_{89}NO_4$ , determined by positive ESI-MS data for the  $[M+Na]^+$  at  $m/z$  718. The IR absorption bands data at 3340, 2906, 1620, 1465, and 715  $cm^{-1}$  indicated the presence of hydroxyls, amide groups, and long aliphatic chains. The NMR spectra of **2** (Table 2) showed an amide NH signal (1H,  $\delta_H$  8.39, d,  $J = 8.5$  Hz), a carbonyl ( $\delta_C$  173.3, C-1') and a group of proton signals (66H,  $\delta_H$  1.23–1.44, br.s), and two terminal methyls (6H,  $\delta_H$  0.87, t), which indicated that **2** might belong to the ceramide class [17, 18]. The characteristic signals of 2-amino-1,3,4-triol of the hydrocarbon chain were observed at  $\delta_H$  5.06 (1H, m, H-2), 4.49 (1H, dd,  $J = 10.9, 4.9$  Hz, H-1a), 4.45 (1H, dd,  $J = 11.7, 5.8$  Hz, H-1b), 4.37 (1H, dd,  $J = 5.9, 5.2$  Hz, H-3), 4.24 (1H, m, H-4) in the  $^1H$  NMR spectra, and at  $\delta_C$  53.8 (C-2), 62.3 (C-1), 76.8 (C-3), 73.1 (C-4) in the  $^{13}C$  NMR spectra. The  $^1H$  NMR showed signals corresponding to six methyl protons at  $\delta_H$  0.87 (6H, t,  $J = 6.7$  Hz, H-16 and H-28') and a very strong aliphatic methylene band at  $\delta_H$  1.23–1.44. The  $^{13}C$  NMR spectrum of **2** showed one quaternary carbon at  $\delta_C$  173.3 (C-1') and two terminal methyl groups at  $\delta_C$  14.3. The presence of a triplet signal at  $\delta_H$  2.45 (2H, t,  $J = 7.5$  Hz, H-2') due to the methylene protons connected to amide carbonyl indicated that the *N*-acyl moiety in **2** was a nonhydroxy fatty acid [19]. The structural elucidation and assignments of complete proton and carbon signals were achieved by 2D NMR (HSQC, HMBC, and  $^1H-^1H$  COSY) techniques and chemical methods. The  $^1H-^1H$  COSY spectra showed the C<sub>1</sub>-C<sub>2</sub>-C<sub>3</sub>-C<sub>4</sub>-C<sub>5</sub> connectivity. The carbonyl group position was assigned by the long-range HMBC correlations between H-3 at  $\delta_H$  4.37 and C-2 at  $\delta_C$  53.8, between H-1 at  $\delta_H$  4.49, 4.45 and C-2, and between H-4 at  $\delta_H$  4.24 and C-2.

The length of the long-chain base (LCB) and the fatty acid (FA) was determined by ESI-MS (Fig. 2). The positive ESI-MS of **2** showed a quasimolecular ion at  $m/z$  718  $[M+Na]^+$ , and the significant fragment ions at  $m/z$  317  $[M+H-C_{27}H_{55}]^+$ , 330  $[M-C_{26}H_{53}]^+$ , 540  $[M-C_{11}H_{23}]^+$ , 478  $[M-C_{12}H_{25}-CHOH-H_2O]^+$ , and 422  $[M-LCB]^+$  in the ESI-MS indicated the presence of an amino alcohol chain of 16 carbon atoms. Moreover, fragment ions at  $m/z$  678, 664, 646, 407, 379, 273, 229, and 169 are the main ions of compound **2**, which predicts 16 and 28 carbons in the LCB and FA, respectively.

The relative stereochemistry of **2** at C-2, C-3, and C-4 was proposed to be 2*S*, 3*S*, and 4*R*, since the  $^1H$  NMR spectral data of **2** [H-1a at  $\delta_H$  4.49 (dt,  $J = 10.9, 4.9$  Hz), H-1b at  $\delta_H$  4.45 (dt,  $J = 10.8, 5.8$  Hz), H-2 at  $\delta_H$  5.06 (m), H-3 at  $\delta_H$  4.37 (dd,  $J = 5.9, 5.2$  Hz), and H-4 at  $\delta_H$  4.24 (m)] were in good agreement with those of natural and synthetic ceramides reported in the literature [16, 20]: (2*S*,3*S*,4*R*)-2-(2'-hydroxytetracosanoylamino)hexadecane-1,3,4-triol isolated from the starfish *Acanthaster planci* [H-1a at  $\delta_H$  4.52 (dd,  $J = 10.7, 4.5$  Hz), H-1b at  $\delta_H$  4.43 (dd,  $J = 10.6, 5.0$  Hz), H-2 at  $\delta_H$  5.12 (m), H-3 at  $\delta_H$  4.36 (dd,  $J = 4.6, 6.6$  Hz), and H-4 at  $\delta_H$  4.29 (m)]. Based on the  $^1H$  NMR chemical shifts of the chiral center and the data of optical rotation compared with those of the reported ceramides, (2*S*,3*S*,4*R*)-2-(2'-hydroxytetracosanoylamino)hexadecane-1,3,4-triol [16, 20], compound **2** has the same absolute configuration at asymmetric centers 2, 3, and 4. Including biogenetic considerations, compound **2** was assigned to be (2*S*,3*S*,4*R*)-1,3,4-trihydroxy-2-octacosanoylaminohexadecane, named zephyranamide B.




Fig. 2. ESI-MS fragment analysis of compounds **1** and **2**.

## EXPERIMENTAL

**General Methods.**  $^1H$  NMR and  $^{13}C$  NMR, COSY, HSQC, and HMBC spectra: Bruker spectrometers operating at 500 MHz; ESI-MS: Agilent 1100 LC/MSD SL; IR spectra: IMPACT 400 (KBr); JASCO P-1020 optical rotation apparatus.

**Plant Material.** Bulbs of *Zephyranthes candida* were collected from Nanjing Agricultural University, Jiangsu province, P. R. China, in August, 2006. A voucher specimen documenting the collection was authenticated at the Herbarium, Institute of Botany (Nanjing Botanical Garden Mem. Sun Yat-Sen), Jiangsu province and Chinese Academy of Sciences, where it was deposited.

**Extraction and Purification.** Air-dried, powdered bulbs of *Zephyranthes candida* (10.2 kg) were extracted three times with 95% EtOH at room temperature for two weeks. The aqueous ethanol phase was evaporated under reduced pressure and the initial residue dried in *vacuo*. The resulting residue was dissolved in  $H_2O$  and re-extracted with petroleum ether,  $CHCl_3$ , and then  $CHCl_3$ -MeOH (3:2). The extracts portion of  $CHCl_3$  and  $CHCl_3$ -MeOH (3:2) were combined and evaporated, and subjected to silica gel column chromatography eluting with  $CHCl_3$ -MeOH [99:1→97:3→95:5→9:1→8:2→7:3→6:4→1:1] to furnish eight fractions (fractions 1 to 8). Fraction 2 was then chromatographed on silica gel eluting with petroleum ether-EtOAc [100:0→90:10→80:20→70:30] to furnish four fractions (fractions 1 to 4); the second fraction was further purified using  $CHCl_3$ -MeOH as eluent with gradient polarity to afford **1** (12.0 mg) and **2** (8.0 mg).

**Zephyranamide A (1)**, white amorphous powder, mp 141–143°C ( $CHCl_3$ -MeOH),  $[\alpha]_D^{25}$   $-3.20^\circ$  (*c* 0.05, pyridine). IR ( $\nu_{max}$ , KBr,  $cm^{-1}$ ): 3334, 3202, 2902, 1623, 1527, 1482, and 710. ESI-MS:  $m/z$  682  $[M+H]^+$ .

**Zephyranamide B (2)**, white amorphous powder, mp 117–118°C ( $CHCl_3$ -MeOH),  $[\alpha]_D^{25}$   $-3.38^\circ$  (*c* 0.13, pyridine). IR ( $\nu_{max}$ , KBr,  $cm^{-1}$ ): 3340, 2906, 1620, 1465, and 715. ESI-MS:  $m/z$  718  $[M+Na]^+$ . For the  $^1H$  NMR and  $^{13}C$  NMR as well as HSQC, HMBC, and COSY spectral data of **1** and **2**, see Tables 1 and 2 and Fig. 1.

## REFERENCES

1. G. R. Pettit, V. Gaddamidi, and G. M. Cragg, *J. Nat. Prod.*, **47**, 1018 (1984).
2. S. Ghosal, S. K. Singh, and R. S. Srivastava, *Phytochemistry*, **25**, 1975 (1986).
3. S. Ghosal, S. K. Singh, and R. S. Srivastava, *Phytochemistry*, **24**, 151 (1985).
4. S. Ghosal, S. K. Singh, and G. Unnikrishnan, *Phytochemistry*, **26**, 823 (1987).
5. B. N. Su, R. Misico, E. J. Park, B. D. Santarsiero, A. D. Mesezar, H. H. S. Fong, J. M. Pezzuto, and A. D. Kinghorn, *Tetrahedron*, **58**, 3453 (2002).
6. C. C. F. Simo, S. F. Kouam, H. M. P. Poumale, I. K. Simo, B. T. Ngadjui, I. R. Green, and K. Krohn, *Biochem. Syst. Ecol.*, **36**, 238 (2008).
7. B. N. Su and Y. Takaishi, *J. Nat. Prod.*, **62**, 1325 (1999).
8. K. Kondo, H. Shigemori, Y. Kikuchi, M. Ishibashi, T. Sasaki, and J. Kobayashi, *J. Org. Chem.*, **57**, 2480 (1992).
9. M. A. Ouyang, R. Liu, and Y. H. Kuo, *J. Asian Nat. Prod. Res.*, **7**, 761 (2005).
10. X. Li, D. D. Sun, J. W. Chen, L. W. He, H. Q. Zhang, and H. Q. Xu, *Fitoterapia.*, **78**, 490 (2007).
11. N. Kumar, B. Singh, A. P. Gupta, and V. K. Kaul, *Tetrahedron.*, **62**, 4317 (2006).
12. P. Tuntiwachwuttikul, Y. Pootaeng-On, P. Phansa, and W. C. Taylor, *Chem. Pharm. Bull.*, **52**, 27 (2004).
13. G. D. W. F. Kapche, H. Laatsch, S. Fotso, S. F. Kouam, P. Wafo, B. T. Ngadjui, and B. M. Abegaz, *Biochem. Syst. Ecol.*, **35**, 539 (2007).
14. M. H. Oueslati, Z. Mighri, H. B. Jannet, and P. M. Abreu, *Lipids.*, **40**, 1075 (2005).
15. F. Leon, I. Brouard, A. Rivera, F. Torres, S. Rubio, J. Quintana, F. Estevez, and J. Bermejo, *J. Med. Chem.*, **49**, 5830 (2006).
16. S. Sugiyama, M. Honda, R. Higuchi, and T. Komori, *Liebigs Ann. Chem.*, 349 (1991).
17. T. Natori, M. Morita, K. Akimoto, and Y. Koezuka, *Tetrahedron*, **50**, 2771 (1994).
18. J. M. Gao, Z. J. Dong, and J. K. Liu, *Lipids*, **36**, 175 (2001).
19. J. M. Gao, X. Yang, C. Y. Wang, and J. K. Liu, *Fitoterapia*, **72**, 858 (2001).
20. M. Inagaki, R. Isobe, Y. Kawano, T. Miyamoto, T. Komori, and R. Higuchi, *Eur. J. Org. Chem.*, 129 (1998).